Initial Characterization of the Vitamin D Binding Protein (Gc-Globulin) Binding Site on the Neutrophil Plasma Membrane: Evidence for a Chondroitin Sulfate Proteoglycan

Stephen J. DiMartino and Richard R. Kew
J Immunol August 15, 1999, 163 (4) 2135-2142;

Abstract

The vitamin D binding protein (DBP) is a multifunctional plasma protein that can modulate certain immune and inflammatory responses. The diverse cellular functions of DBP appear to require cell surface binding to mediate these processes. Numerous reports have detected DBP bound to the surface of several cell types and would support the concept of a cell surface binding site for DBP. However, direct evidence for such a molecule has been lacking and essentially nothing is known about its basic biochemical properties. In the present study, radioiodinated DBP was used as a probe to characterize biochemically the neutrophil DBP binding site. Radiolabeled DBP binds to and remains associated with the plasma membrane and is not degraded. Quantitation of DBP binding to either intact cells or purified plasma membranes showed nonsaturable (linear) binding with positive cooperativity, possibly suggesting DBP oligomer formation. Solubilization of cell bound 125I-DBP with various nonionic and zwitterionic detergents demonstrated that DBP binds to a membrane macromolecule that partitions to the detergent insoluble fraction. Moreover, this molecule does not associate with the cytoskeleton. Cross-linking of radiolabeled DBP bound to plasma membranes increased the amount of protein that partitioned to the insoluble fraction, and analysis of these complexes by SDS-PAGE revealed that they may be very large since they did not enter the gel. Finally, treatment of plasma membranes with either proteases or chondroitinase ABC completely abrogated membrane binding of DBP, suggesting that the protein binds to a chondroitin sulfate proteoglycan.

The vitamin D binding protein (DBP),3 also known as Gc-globulin, is a multifunctional plasma protein that can bind several diverse ligands (1, 2). DBP is a member of the albumin and α-fetoprotein gene family and shares considerable amino acid homology with these proteins (3, 4). The protein is synthesized predominantly by hepatocytes and circulates in blood at a concentration of 6–7 μM as a single polypeptide chain with a molecular mass of ∼56 kDa (1). DBP functions to transport vitamin D sterols, acts as a scavenger protein to clear extracellular G-actin released from necrotic cells, and a deglycoslated form of DBP has been shown to be a potent macrophage activating factor (5). In addition, we and others have demonstrated that purified DBP can significantly enhance the chemotactic activity (i.e., cochemotactic activity) of C5a and C5a des Arg (C5-derived peptides) for human (6, 7, 8, 9, 10) and bovine neutrophils (11). DBP has also been shown to augment monocyte and fibroblast chemotaxis to C5-derived peptides (12, 13). However, the chemotactic enhancing properties of DBP appear to be restricted to C5a/C5a des Arg, since this protein cannot enhance the chemotactic activity of formylated peptides, IL-8, leukotriene B4, or platelet activating factor (6, 7, 8, 9, 10, 11). Although DBP appears to be a physiologically important regulator of leukocyte chemotactic activity for activated complement, the mechanism of chemotactic enhancement is not yet known.

Numerous investigators have reported a cell-associated form of DBP in many cell types, including neutrophils (14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27). Cell-associated DBP is not a novel cellular form but rather plasma-derived DBP bound to the cell surface (22). DBP bound to the plasma membrane of neutrophils appears to play an essential role in enhancing chemotaxis to C5-derived peptides (28, 29). It has been demonstrated that the binding and uptake of DBP by neutrophils is temporally correlated with generation of cochemotactic activity, and prevention of cellular uptake by an Ab (DBP pretreated with polyclonal anti-DBP) also precludes formation of cochemotactic activity (29). Moreover, the binding of DBP to its putative cell surface binding site may be important for several other functions of the protein, including delivery of vitamin D sterols, clearance of DBP-G actin complexes, and activation of macrophages. Therefore, a better understanding of the biochemical characteristics of its cell surface binding site is necessary to understand the diverse cellular functions of DBP. The goal of the present paper was to characterize the biochemical properties of the putative DBP binding site on human neutrophils. While a great deal of evidence supports the existence of such a cell surface molecule, essentially nothing is known about its basic biochemical properties. In this report, we demonstrate that radioiodinated DBP binds to a molecule on the neutrophil plasma membrane that partitions to the detergent insoluble fraction but is not associated with the cytoskeleton. Moreover, the cross-linked DBP-binding site complex does not enter an SDS-PAGE gel, suggesting that the complex may be very large. The unusual binding and biochemical characteristics of the binding site suggests that DBP may interact with large glycosaminoglycan (GAG)-containing macromolecules. Enzymatic treatment of plasma membranes confirmed that DBP binds to a chondroitin sulfate proteoglycan.

Materials and Methods

Reagents

Purified human DBP was purchased from Biodesign International (Kennebunkport, ME). PMSF and 1,10-phenanthroline were purchased from Sigma (St. Louis, MO). All other protease inhibitors were purchased from Bachem (Torrence, CA). The chemical cross-linkers, dithiobis(succinimidylpropionate) (DSP), 3,3′-dithiobis(sulfosuccinimidylpropionate) (DTSSP), and ethylene glycol bis(sulfosuccinimidylsuccinate) (sulfoEGS) were purchased from Pierce (Rockford, IL). Cytochalasin D and the detergents Triton X-100 (TX-100), Triton X–114 (TX-114), digitonin, n-octyl B-d-glucopyranoside (octyl glucoside), and 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) were purchased from Sigma. Heparinase I (from Flavobacterium heparinium), heparinase III (heparitinase, from F. heparinium), chondroitinase (ABC from Proteus vulgaris, AC from F. heparinium), trypsin, and chymotrypsin were purchased from Sigma. Sialidase (neuraminidase) was purchased from Boehringer Mannheim (Indianapolis, IN). Human leukocyte elastase and cathepsin G were obtained from Elastin Products (Owensville, MO). The bicinchoninic acid (BCA) and microBCA protein assay kits were obtained from Pierce.

Isolation of human neutrophils

Neutrophils were isolated from the venous blood of healthy, medication-free, paid volunteers (who gave informed consent) using a standard three-step isolation procedure described previously (29).

Radioiodination of DBP

Purified DBP (200–400 μg) was incubated with one Iodobead (Pierce) and 1 mCi of Na125I (DuPont-NEN, Wilmington, DE) for 5 min. The reaction was terminated by removing the solution from the Iodobead. Free Na125I was separated from 125I-DBP by gel filtration on a PD-10 (Sephadex G-25; Pharmacia LKB, Piscataway, NJ) desalting column. The 125I-DBP was concentrated using a Centricon 30 microconcentrator (m.w. cutoff, 30 kDa; Millipore, Bedford, MA). TCA at 10% was used to determine the percentage of protein-associated counts. Radioiodinated DBP preparations generally had >99% of the total counts precipitable with 10% TCA. Finally, protein concentration was measured using the microBCA assay, and an aliquot was examined by SDS-PAGE and autoradiography to determine its purity.

Disruption and subcellular fractionation of neutrophils

Purified neutrophils were suspended at 75–100 × 106 cells/ml in ice-cold disruption buffer (100 mM KCl, 3 mM NaCl, 3.5 mM MgCl2, 10 mM HEPES, 1 mM ATP (pH 7.4), containing 1 mM PMSF, 2 mM 1,10-phenanthroline, 100 μM E-64, and 25 μM pepstatin A), then added to a prechilled nitrogen cavitation bomb (Parr Instrument Company, Moline, IL). The cells were equilibrated to 350 psi with constant stirring for 20 min and then collected in a dropwise fashion into 125 mM EGTA (pH 7.4) to achieve a final concentration of 1.25 mM EGTA (30). Nuclei and unbroken cells were removed by centrifugation at 800 × g for 10 min at 4°C. Prechilled (4°C) Percoll gradients (Pharmacia LKB) were prepared by progressively underlaying 2.2 ml of each increasing density (1.05, 1.09, and 1.12 g/ml) in a 14 × 89-mm Ultra-Clear centrifuge tube (Beckman Instruments, Palo Alto, CA). The supernatant from the nitrogen cavitation (∼3 ml) was layered on top of the Percoll gradient and centrifuged at 50,000 × g for 50 min in a prechilled SW41 swinging bucket rotor (Beckman) (31). Fractions were collected by aspiration using sterile, glass Pasteur pipettes. Percoll was removed from the fractions by centrifugation at 100,000 × g for 60 min at 4°C.

The purified neutrophil subcellular fractions were resuspended in equal volumes of HBSS, the total protein content then was measured using the microBCA assay, and the purity of each subcellular fraction was assessed using marker assays for plasma membranes and each granule population (30). The purity of the plasma membrane and azurophil granule preparations were evaluated using quantitative assays for alkaline phosphatase and myeloperoxidase activities, respectively. The purity of gelatinase granules was assessed using gelatin zymography. A Western blot for lactoferrin was used to evaluate the purity of specific granules. Plasma membrane fractions contained 97 ± 3.2% (n = 11) of the total alkaline phosphatase activity. The azurophil granules possessed 72 ± 6.3% (n = 9) of the total myeloperoxidase (MPO) activity with balance of the MPO activity found in the specific granule fraction. The nonquantitative gelatinolytic and lactoferrin assays revealed that the bulk of the gelatinase activity was in the gelatinase granule fraction, whereas the majority of the lactoferrin was localized to the specific granule fraction.

Quantitative binding assay

Neutrophils (107 cells/sample) or purified neutrophil plasma membranes (5 μg total protein/sample) were incubated with 125I-DBP in HBSS containing 0.1% BSA (assay buffer) in a total volume of 100 μl. Samples were incubated on ice (2°C) for 60 min. After the incubation period, the samples were applied to a Millipore vacuum filtration manifold to separate free from bound radiolabeled ligand. Samples were separated using 25-mm, circular Durapore type VV filters with 0.1-μm pore size (Millipore). The filters were presoaked with 1% BSA (in HBSS) to block nonspecific binding of protein. After vacuum separation, the material bound to the filters was washed four times with 1 ml of ice-cold assay buffer, then the filters counted in a gamma counter for the amount of bound 125I-DBP. All samples were assayed in triplicate or quadruplicate. For each concentration of radiolabeled DBP, a buffer control was included that contained no cells or membranes. Radioactivity that bound to filters under these conditions was considered the background value and was subtracted from the appropriate samples.

Preparation of neutrophil detergent lysates

Detergent lysates of neutrophils were prepared by adding 100 μl of 1% detergent, 50 mM HEPES (pH 7.4) containing 20 mM benzamidine, 10 mM EDTA, 10 mM NaN3, as well as the following inhibitors added fresh immediately before lysis: 2 mM PMSF, 2 mM 1,10-phenanthroline, 0.5 mM E-64, 0.2 mM 3,4-dichloroisocoumarin, 0.1 mM leupeptin, and 0.1 mM pepstatin. Lysates were vortexed thoroughly until all particulate matter was solubilized (usually 5–10 s) and then placed at 37°C for 60 min. The detergent insoluble material was then pelleted by centrifuging the lysates in a microfuge for 10 min at 15,000 × g at 4°C.

PAGE and autoradiography

Samples were separated by SDS-PAGE using the discontinuous buffer system described by Laemmli (32). Samples were prepared for electrophoresis by boiling (100°C) for 7 min with an equal volume of electrophoresis sample buffer (0.125 M Tris (pH 6.8), 20% glycerol, 4% SDS) containing 0.2 M DTT as the reducing agent and separated on a homogenous 10% polyacrylamide separating gel with a 4% polyacrylamide stacking gel. After electrophoresis, the gels were stained, destained, dried, and exposed to x-ray film at −80°C.

Results

Previous work from our laboratory has demonstrated that the binding of DBP to neutrophils is essential for the chemotaxis enhancement of C5a (28, 29). Moreover, analysis of neutrophil-associated DBP by immunofluorescence suggested that the protein was localized to the cell surface (19). However, it was not clear whether neutrophils internalized and processed DBP or whether the protein remained bound to the cell surface. To determine the fate of DBP bound to neutrophils, cells were allowed to bind 125I-DBP for 45 min at 37°C, washed, then were disrupted by nitrogen cavitation, and the subcellular fractions were isolated and counted for radioactivity. Fig. 1⇓ demonstrates that > 87% of the bound DBP associated with the plasma membrane fraction. Subsequent analysis of the plasma membranes showed that >98% of the radioactivity was precipitable with 10% TCA. In addition, SDS-PAGE revealed that the plasma membrane-bound radioiodinated DBP migrated at 56 kDa, the same as purified native DBP, indicating that the protein was not degraded (data not shown). These results demonstrate that DBP binds to, and remains associated with, the plasma membrane.

FIGURE 1.
FIGURE 1.

DBP associates with the neutrophil plasma membrane. Purified neutrophils from one donor were incubated in HBSS with 100 nM 125I-DBP for 45 min at 37°C. Cells were washed with ice-cold HBSS, then resuspended in disruption buffer at 75 × 106 cells/ml. After disruption in a nitrogen cavitation bomb, the subcellular fractions were separated using Percoll gradients. The fractions were isolated, washed in cold disruption buffer, and counted for radioactivity. Data is expressed as fmols of 125I-DBP associated with each fraction.

The binding characteristics of 125I-DBP to intact neutrophils (107 cells) and neutrophil plasma membranes (5 μg) were investigated using increasing concentrations of radiolabeled ligand. Fig. 2⇓ shows that the binding to either intact cells (Fig. 2⇓A) or neutrophil plasma membranes (Fig. 2⇓B) is linear (nonsaturable) up to 4 μM (Fig. 2⇓A) or 5 μM (Fig. 2⇓B) radiolabeled DBP. These experiments would suggest that the affinity of DBP for its binding site is very low. However, extensive washing of the plasma membranes in a detergent (1% TX-100) or high salt (1 M NaCl)-containing buffer did not remove the previously bound DBP (data not shown). Moreover, 100-fold molar excess of unlabeled DBP could not displace previously bound radiolabeled protein (data not shown), suggesting that the binding was relatively tight. In addition, the nonsaturable binding probably was not due to a large number of binding sites, since a 10-fold reduction in the concentration of membranes (0.5 μg) or cells (106) produced almost identical linear binding curves (data not shown). Another possibility to explain nonsaturable binding is that the binding site induces oligomerization of the DBP. Therefore, to examine this potential mechanism, a competitive binding assay was performed where radiolabeled protein was bound to membranes in the presence of increasing concentrations of unlabeled DBP (Fig. 3⇓). If the interaction of DBP with its binding site is 1 mol per mol, then a competitive binding assay should demonstrate decreasing levels of radiolabel bound with increasing amounts of unlabeled competitor protein. Fig. 3⇓ clearly shows that unlabeled protein increases the amount of radiolabeled DBP bound to the membranes at the lower concentrations, indicating some form of positive cooperativity, perhaps oligomerization of the ligand. These data demonstrate that DBP binding to the neutrophil plasma membrane is nonsaturable and suggest that the binding site induces oligomerization of DBP.

FIGURE 2.
FIGURE 2.

Binding of radioiodinated DBP to neutrophils and neutrophil plasma membranes. Purified neutrophils (107) or neutrophil plasma membranes (5 μg total protein) were incubated in HBSS containing 0.1% BSA with the indicated concentrations of 125I-DBP in a total volume of 0.1 ml. Samples were incubated on an ice slurry (2°C) for 60 min, and free ligand was then separated from the bound using a vacuum filtration device. Filters were counted for radioactivity, and the data are presented as fmols radioiodinated DBP bound either per 106 neutrophils or per μg membrane protein (n = 2–4).

FIGURE 3.
FIGURE 3.

Competitive binding of radioiodinated DBP to neutrophil plasma membranes. Purified neutrophil plasma membranes (5 μg) were incubated in HBSS containing 0.1% BSA with 1 μM 125I-DBP plus the indicated concentrations of unlabeled DBP in a total volume of 0.1 ml. Samples were incubated on an ice slurry (2°C) for 60 min, and free ligand was then separated from the bound using a vacuum filtration device. Filters were counted for radioactivity, and the data are presented as fmols radioiodinated DBP bound per μg membrane protein (n = 2).

Our previous attempts to identify the DBP binding site by immunoprecipitating unlabeled DBP bound to surface-labeled cells were largely unsuccessful. In retrospect, this was not surprising given the unusual binding characteristics (Figs. 2⇑ and 3⇑). Therefore, a less selective approach was chosen to elucidate the biochemical properties of the DBP binding site on neutrophils. Since nonionic and zwitterionic detergents have been used extensively for the solubilization and characterization of numerous membrane proteins, we compared several detergents for their ability to solubilize membrane-bound DBP. Five nondenaturing detergents with different structures were employed: the nonionic detergents TX-100, TX-114, octyl glucoside, digitonin, and the zwitterionic detergent CHAPS. In addition, a complete protease inhibitor mixture was added to each detergent lysis buffer immediately before solubilization. For each detergent, solubilization revealed that ∼50% of the total cell-associated radiolabeled DBP remained with the insoluble fraction (Fig. 4⇓). Additional washes (total of six) of the insoluble material in 1% detergent liberated <10% of the previously bound DBP. Radioiodinated DBP, by itself, added to detergent was essentially 100% detergent soluble. Solubilization on ice (2°C), instead of 37°C, yielded no detectable differences in either the percent soluble vs insoluble DBP or in the m.w. of radioiodinated DBP by SDS-PAGE (data not shown). The percent distribution of the radiolabeled DBP was not altered if, during the preincubation step, neutrophils were either kept at 2°C, or in buffer lacking calcium and magnesium ions (PBS), or pretreated with phosphatidylinositol specific phospholipase C (5 U/ml) (data not shown). Furthermore, conditions designed to break divalent cation-dependent (10 mM EDTA) or ionic interactions (1 M NaCl) had no effect on the distribution of DBP to the insoluble fraction (Fig. 5⇓). However, denaturing conditions (2% SDS or 0.1 M sodium carbonate (pH 11.0)) completely solubilized the protein (Fig. 5⇓). These data indicate that a large percentage of DBP associates with the insoluble fraction of neutrophils solubilized under nondenaturing conditions.

FIGURE 4.
FIGURE 4.

DBP associates with the insoluble fraction of neutrophils lysed using nonionic detergents. Purified neutrophils were incubated in HBSS with 100 nM 125I-DBP for 60 min at 37°C. After washing, the cells were lysed using one of five detergents as follows: (a) 0.5% TX-114 for 1 h on ice, (b) 1% TX-100 for 1 h at 37°C, (c) 1% octyl glucoside for 1 h on ice, (d) 1% digitonin for 1 h at 37°C, (e) 1% CHAPS for 1 h at 37°C. All lysates included a protease inhibitor mixture (see Materials and Methods). The soluble and insoluble fractions were separated (15,000 × g for 10 min) and counted for radioactivity. Data are expressed as the percent of total cell associated radioactivity found in each fraction. The results represent the mean + SD of three to six separate experiments performed in duplicate using neutrophils from different donors.

FIGURE 5.
FIGURE 5.

SDS and sodium carbonate (pH 11.0) can release DBP from the TX-100-insoluble fraction of a neutrophil lysate. Purified neutrophils were incubated in HBSS with 100 nM 125I-DBP for 60 min at 37°C. After washing, the cells were lysed in 1% TX-100, which contained one of the following: (a) 10 mM EDTA; (b) 1 M NaCl; (c) 2% SDS; (d) 0.1 M sodium carbonate (pH 11.0). For the samples containing SDS and sodium carbonate, DNase I was added to decrease viscosity of the lysate (due to DNA released from the nuclei), which facilitated separation of the soluble and insoluble fractions. DNase I had no effect on the distribution of DBP (data not shown). Data are expressed as the percent of total cell associated radioactivity found in each fraction. The results represent the mean + SD of two to four separate experiments performed in duplicate using neutrophils from different donors.

The detergent-insoluble cell fraction contains many cell surface proteins, as well as cytoskeletal elements (33). Accordingly, to determine whether DBP was interacting with cytoskeletal proteins indirectly via cell surface molecules, neutrophils first were pretreated with 10 μM cytochalasin D (to disrupt the actin cytoskeleton) before incubation with radiolabeled DBP and lysis in TX-100. Cytochalasin D treatment had no effect on the partitioning of DBP to the insoluble fraction (52% TX-100 insoluble, 48% soluble). Moreover, radiolabeled DBP also associated with the detergent-insoluble fraction after binding to neutrophil plasma membranes (56% TX-100 insoluble, 44% soluble), which lack a cytoskeleton. These data suggest that DBP binds to a cell surface molecule(s) that is insoluble for reasons other than association with the cytoskeleton.

Partitioning of DBP to the detergent-insoluble fraction could be an artifact of solubilization, i.e., solubilization might disrupt the DBP-binding site complex, and the liberated DBP could then bind artifactually to a molecule that partitions with the insoluble fraction. To confirm that, before cell lysis, DBP associates with a molecule that will partition to the detergent-insoluble fraction, DBP was cross-linked to neutrophils using: DSP (membrane permeable cross-linker), DTSSP (water-soluble analogue of DSP), and sulfo-EGS (water soluble, nonmembrane permeable). Neutrophils were incubated with radiolabeled DBP at 37°C followed by cross-linking for 30 min on ice. Treatment with all cross-linkers resulted in a significant accumulation of DBP in the TX-100 insoluble fraction, as compared with the control sample (Fig. 6⇓). However, >95% of the DBP-binding site complex was solubilized when sulfo-EGS cross-linked cells were lysed in 1% TX-100 containing 0.1 M sodium carbonate (pH 11.0) (Fig. 6⇓). This indicates that the covalent cross-links are not responsible for causing the observed insolubility, since sodium carbonate does not break the covalent cross-links of sulfo-EGS. In addition, this data demonstrates that the cross-linked DBP-binding site complex can be solubilized using denaturing conditions. This experiment demonstrates that DBP binds to a molecule(s) that is destined to partition to the insoluble fraction following detergent solubilization.

FIGURE 6.
FIGURE 6.

Homobifunctional chemical cross-linkers increase the amount of DBP associated with the TX-100 insoluble fraction of neutrophil lysates. Purified neutrophils were incubated in HBSS with 100 nM radioiodinated DBP for 30 min at 37°C. The cells were washed, then placed on an ice slurry and incubated with 1 mM DSP, 1 mM DTSSP, 1 mM sulfo-EGS, or no cross-linker for 30 min. After cross-linking, the reaction was terminated by addition of Tris (pH 8.0; final concentration of 10 mM). The cells were then washed once in ice-cold HBSS and lysed for 1 h at 37°C using either 1% TX-100 (pH 7.4) or 1% TX-100 in 0.1 M sodium carbonate (pH 11.0). The soluble and insoluble fractions were separated and counted for radioactivity. Data are expressed as the percent of total cell-associated radioactivity found in each fraction. The results represent the mean + SD of two to five separate experiments using neutrophils from different donors.

DBP was cross-linked to intact neutrophils to determine the m.w. of its binding site. Both the detergent-soluble and -insoluble fractions of DBP cross-linked to neutrophils were analyzed by SDS-PAGE and autoradiography (Fig. 7⇓). In the soluble fractions, DBP was observed only at its native m.w. (56 kDa). However, in the insoluble fractions, DBP was observed in two large complexes, one that did not enter the stacking gel and another that appeared at the top of the separating gel. Interestingly, the control sample showed that DBP could participate in these complexes even in the absence of cross-linker, although this was a minor component (Fig. 7⇓). When DTSSP concentrations greater than 1000 μM were used, all the radioiodinated DBP shifted to the two large complexes at the top of the gel (data not shown). The cross-linked complexes probably were not due to random collisional interactions, since it has been shown that random collisional cross-links are observed only when cross-linking is performed at elevated temperatures and high protein concentrations (34). Furthermore, cross-linking of DBP, in the absence of cells, generated no intermolecular complexes, despite being performed at a higher protein concentration (2 μM) and cross-linking temperature (37°C) (data not shown). These data demonstrate that, on neutrophils, DBP interacts with a large detergent-insoluble complex that does not enter an SDS-PAGE gel.

FIGURE 7.
FIGURE 7.

SDS-PAGE and autoradiography of DBP cross-linked to neutrophils. Purified neutrophils were incubated in HBSS with 250 nM 125I-DBP for 30 min at 37°C. The cells were then washed and resuspended in ice-cold HBSS. Various concentrations of DTSSP were added, and the mixtures were incubated for 30 min on ice. The cross-linking reaction was stopped by adding Tris (pH 8.0) to a final concentration of 10 mM and then incubating on ice for 15 min. The cells were washed and then lysed in 1% TX-100 for 1 h at 37°C. The soluble and insoluble fractions were separated and counted for radioactivity. Next, samples were boiled in SDS buffer and ∼25,000 cpm were loaded into each lane of a 10% SDS-PAGE gel with a 4% stacking gel. All samples shown are nonreduced. The results essentially were identical for the lipid soluble cross-linker DSP (data not shown).

The unusual binding and biochemical characteristics of the binding site suggest that DBP may interact with large GAG-containing macromolecules. To address this possibility directly, intact neutrophils were treated with either proteases (pronase or trypsin, 1 mg/ml) or a mixture of GAG lyases (heparinase, heparitinase, and chondroitinase ABC, each at 1 U/ml) for 30 min at 37°C. Either treatment of neutrophils significantly reduced subsequent DBP binding to ∼60% of control levels. This enzymatic approach was investigated further using purified neutrophil plasma membranes and the quantitative binding assay utilized above. Fig. 8⇓A demonstrates that treatment of membranes with the broad specificity proteases, trypsin and chymotrypsin, completely eliminated subsequent DBP binding to membranes. Treatment of plasma membranes with the two major neutrophil proteases, elastase and cathepsin G, revealed that elastase treatment reduced DBP binding by >90%, whereas cathepsin G had no significant effect (Fig. 8⇓A). Treatment of plasma membranes with GAG lyases showed that only chondroitinase ABC could significantly diminish subsequent DBP binding (Fig. 8⇓B). In addition, DBP binding to membranes was also significantly reduced following treatment with chondroitinase AC, indicating that chondroitin sulfate B (dermatan sulfate) probably is not involved in DBP binding to neutrophils. These results indicate that DBP binds to a chondroitin sulfate proteoglycan on the neutrophil plasma membrane.

FIGURE 8.
FIGURE 8.

Effect of enzymatic treatment on the binding of DBP to plasma membranes. A, Protease treatment, 10 μg of plasma membranes were incubated in HBSS for 20 min at 37°C with either buffer alone or one of the following proteases: trypsin (1 mg/ml), chymotrypsin (1 mg/ml), elastase (1 μM), or cathepsin G (1 μM). B, GAG lyase treatment, 10 μg of plasma membranes were incubated in PBS (for heparinase, heparitinase, and sialidase) or 50 mM Tris, 60 mM sodium acetate (pH 8.0; for chondroitinase ABC) for 20 min at 37°C with buffer alone or one of the following: heparinase (5 U/ml), heparitinase (5 U/ml), sialidase (2 U/ml), or chondroitinase ABC (5 U/ml). Following this incubation, the membranes were pelleted at 14,000 × g for 20 min at 4°C, and then were resuspended in HBSS 0.1% BSA containing 100 nM 125I-DBP and were incubated for 1 h on ice. The samples were then filtered and washed as described in Materials and Methods. Filters were counted for radioactivity and the blank values subtracted from each sample value. All buffer controls (HBSS, PBS, Tris) had identical blank values. Data is expressed as fmols DBP bound as a percent of the control values. Data represents the mean + SEM of three to six separate experiments using membranes isolated from three different donors.

Discussion

Numerous investigators have reported that DBP associates with the plasma membrane of human blood monocytes, lymphocytes, and neutrophils (14, 15, 16, 17, 18, 19), the B lymphoblastoid cell line Raji (20), HL-60 and U937 cell lines (21, 22), human placental trophoblast and smooth muscle cells (23, 24), rat pancreatic acinar cells (25), porcine kidney tubule cells (26), and human sperm (27). With few exceptions (i.e., hepatocytes) it has been shown that the great majority of cells do not synthesize DBP found on their cell surface, but incorporate it from the extracellular fluids (22). Thus, DBP appears to bind to many diverse types of nucleated cells. However, one possible exception is RBC, since we have been unable to detect binding of radioiodinated DBP to purified, washed human RBC (R. Kew, unpublished observations). Despite the large number of reports that support the existence of a cell surface binding site for DBP, direct evidence for such a molecule has been lacking. In this paper, biochemical data characterizing the properties of the neutrophil DBP binding site are presented. The results show: 1) DBP binds to and remains associated with the plasma membrane and is not degraded; 2) DBP binding to either intact cells or plasma membranes is nonsaturable binding and shows positive cooperativity, possibly suggesting DBP oligomer formation; 3) DBP binds to an integral membrane macromolecule that partitions to the detergent insoluble fraction, and this molecule does not associate with the cytoskeleton; 4) cross-linking of membranes increases the amount of DBP that partitions to the insoluble fraction, and SDS-PAGE analysis revealed that these complexes may be very large since they did not enter the gel. 5) Enzymatic treatment of plasma membranes showed that DBP binds to a chondroitin sulfate proteoglycan. These properties of the DBP binding site clearly indicate that the molecule is not a classic high-affinity, single binding site receptor, but may be one or more heterogenous GAG-containing macromolecules.

The binding of radioiodinated DBP to neutrophils (Fig. 2⇑) (29) is remarkably similar, in terms of kinetics and total amount per million cells, to the 125I-DBP binding to porcine kidney tubule cells (26) and the B lymphoblastoid cell line Raji (20) reported previously. Moreover, DBP bound to porcine kidney tubule cells could not be displaced by 100-fold molar excess of unlabeled ligand (26), similar to what was reported herein. The two previous reports also showed that cell-associated DBP was degraded as evidenced by a high percentage of TCA soluble counts (20, 26). In contrast, we observed that neutrophils do not degrade 125I-DBP and have often found that DBP is remarkably resistant to neutrophil-mediated proteolysis, despite the fact that these cells are often referred to as “bags of proteases.” We have observed that several cell types (neutrophils, U937 cells, HL-60 cells) can hydrolyze the 125I label (depending on the type of iodination procedure employed) without degrading DBP, thus producing a false positive reading by TCA precipitation or SDS-PAGE and autoradiography (R. Kew et al., unpublished observations). Nevertheless, the similarities in binding suggest that many cell types may possess a common cell surface binding site for DBP. A dissociation constant to measure the relative affinity of DBP for its binding site could not be obtained by Scatchard analysis because there was no saturation point in the binding isotherm (Fig. 2⇑). However, the nonsaturable nature of DBP binding may indicate an alternative binding mechanism, such as an adsorptive process, as suggested previously (26).

Neutrophil lysates, from cells preincubated with radiolabeled DBP, demonstrated that the binding site for DBP partitions equally between the detergent-soluble and -insoluble fractions. Non-ionic detergents vary in their ability to solubilize membrane macromolecules. For example, the formyl peptide receptor is only partially soluble (50%) in TX-100 but is completely soluble in octyl glucoside (35). However, in the present study, the DBP binding site was ∼50% soluble in all detergents examined. The detergent-soluble fraction probably represents free DBP that was released from cells during solubilization. Purified DBP added to TX-100 was 100% detergent soluble. Furthermore, cell-bound DBP that partitioned to the soluble fraction was always observed at its native m.w. (56 kDa) when cross-linked cells or membranes were analyzed by either SDS-PAGE or gel filtration chromatography, indicating that the detergent-soluble DBP did not form a complex. In contrast, the detergent-insoluble fraction appears to represent DBP bound to its cell surface binding site. The association with the insoluble fraction appears to be relatively tight because 1 M NaCl, low pH, and 100-fold molar excess of unlabeled protein could not dissociate radioiodinated DBP from the insoluble fraction. Moreover, cross-linkers greatly enhanced the amount of DBP in the insoluble fraction, probably by preventing the dissociation of DBP from its binding site. Denaturing conditions, such as 2% SDS or 0.1 M sodium carbonate (pH 11) solubilized 94% or 97%, respectively, of the DBP bound to cells. Thus, the DBP-binding site complex could be solubilized with anionic detergents or extreme alkaline conditions. However, a small percentage of cell-associated DBP remained insoluble (SDS-resistant) when neutrophils were solubilized with SDS under control (non cross-linked) conditions (Figs. 5⇑ and 7⇑). It is interesting to note that 6 ± 4% of DBP was insoluble in SDS (Fig. 5⇑), whereas ∼8.5% (determined by densitometry) of the cell-associated DBP was SDS-resistant in Fig. 7⇑ (control lane). Although SDS can solubilize the majority of cell-associated DBP, a small percentage (5–10%) remains insoluble, and cross-linking increases this fraction (Fig. 7⇑). SDS-resistant (insoluble) material would not be able to enter an SDS-PAGE gel and would appear at the top of the stacking gel (Fig. 7⇑).

Nonionic detergents interact with membrane lipids and the hydrophobic domains of proteins (33). While they are quite effective at solubilizing membrane proteins and lipids, nonionic detergents are ineffective at breaking charge-dependent interactions and associate poorly with very hydrophilic molecules (33). Characterization of the detergent-insoluble cell fraction has shown that the cytoskeleton (a complex of hydrophilic proteins) is the major fraction remaining from cells solubilized with nonionic detergents (36, 37). Furthermore, some cell surface molecules that interact with the actin cytoskeleton have also been shown to distribute to the detergent-insoluble fraction. For example, the integrins, which are known to interact directly with the cytoskeleton, partition with the detergent-insoluble fraction (38). In neutrophils, β2 integrins translocate to the TX-100 insoluble fraction after cells are stimulated with TNF-α (39). Likewise, in platelets, glycoprotein IIb–IIIa integrin becomes incorporated into the detergent-insoluble fraction upon platelet activation (40). For both models, receptor association with the insoluble fraction is reduced by pretreating the cells with cytochalasins. In contrast, the hyaluronan receptor (CD44) associates with the TX-100 insoluble fraction of cells, but not the actin cytoskeleton, and detergent insolubility of CD44 is not affected by cytochalasin pretreatment (41). Therefore, although detergent insolubility often suggests a linkage with the cytoskeleton, this is not always the case, and other cytoskeleton-independent mechanisms have been described. The detergent insoluble fraction also appears to distinct from detergent-resistant membranes (DRMs), originally described by Brown and Rose (42). DRMs are isolated following TX-100 solubilization of cells on ice (42, 43). In the present study, cells were lysed for 60 min at 37°C, and, under these conditions, DRMs are completely solubilized (42, 43).

Numerous heparan sulfate and chondroitin sulfate proteoglycans have been shown to associate with the insoluble fraction of cells lysed in non-ionic detergents (44, 45, 46, 47, 48). For syndecan-1, a proteoglycan containing both heparan sulfate and chondroitin sulfate, the cytoplasmic domain (which could potentially interact with the cytoskeleton) is not necessary for the observed TX-100 insolubility, nor is the insolubility affected by pretreatment of cells with cytochalasins (48). However, removal of the GAG chains results in complete detergent solubility (48). These observations suggest that interactions involving the anionic GAG chains are responsible for excluding non-ionic detergent. Moreover, proteoglycans can self-aggregate, and it is thought that this hydrophilic, anionic microenvironment serves to exclude nonionic detergents resulting in the partitioning of these molecules to the detergent-insoluble fraction (49, 50, 51). Cell surface proteoglycans are an attractive candidate for the putative DBP binding site. They are a very diverse family of macromolecules that are widely expressed on the plasma membranes of many cell types, including neutrophils (52, 53). Proteoglycans bind a wide variety of ligands and, depending upon the individual proteoglycan, binding can be nonsaturable and may induce ligand oligomerization. In addition, proteoglycans generally partition to the TX-100 insoluble fraction. Because of the large number of anionic GAG chains, many proteoglycans bind SDS poorly and thus do not enter an SDS-PAGE gel. Interestingly, a recent report demonstrated that platelet factor 4 (PF-4) binds to a chondroitin sulfate proteoglycan on the neutrophil plasma membrane, and many of the binding characteristics of PF-4 were similar to those of DBP presented in this report (54).

The putative cell surface binding site for DBP has remained a mystery for many years, probably because of the unusual binding characteristics and the inability of several investigators to isolate a specific membrane macromolecule. The results reported herein suggest that DBP binds to a chondroitin sulfate proteoglycan. Large heterogenous macromolecules, such as cell surface proteoglycans, would certainly explain the unusual cell-binding characteristics of DBP. Definitive identification of the proteoglycan(s) on the neutrophil plasma membrane that bind DBP should help to delineate the mechanisms of C5a cochemotaxis. Furthermore, the neutrophil DBP binding site may also be expressed on a wide variety of cells. However, it is not known if DBP binds to a specific chondroitin sulfate proteoglycan or any GAG-containing macromolecule; additional studies are needed to answer these questions. The information provided in this paper should clarify and focus future investigations aimed at identifying the cellular DBP binding site, and ultimately yield a better understanding of the diverse cellular functions of DBP.

Acknowledgments

We thank Drs. Howard Fleit and Martha Furie (State University of New York, Stony Brook, NY) for their critical review of this manuscript.

Footnotes

  • ↵1 This work was supported in part by a grant (to R.R.K) from the Smokeless Tobacco Research Council (no. 0548) and the Scleroderma Foundation (no. 001099). S.J.D. was supported in part by a Medical Scientist Training Program grant from the National Institutes of Health.

  • ↵2 Address correspondence and reprint requests to Dr. Richard R. Kew, Department of Pathology, State University of New York, Stony Brook, NY 11794-8691. E-mail address: rkew{at}path.som.sunysb.edu

  • ↵3 Abbreviations used in this paper: DBP, vitamin D binding protein; GAG, glycosaminoglycan; DSP, dithiobis(succinimidylpropionate); DTSSP, 3,3′-dithiobis (sulfo-succinimidylproprionate); sulfo-EGS, ethylene glycol bis(sulfo-succinimidylsuccinate); TX, Triton X; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; BCA, bicinchoninic acid.

  • Received February 11, 1999.
  • Accepted June 1, 1999.

References

  1. ↵
    Cooke, N. E., J. G. Haddad. 1989. Vitamin D binding protein (Gc-globulin). Endocr. Rev. 10: 294
    OpenUrlCrossRefPubMed
  2. ↵
    Cleve, H., J. Constans. 1988. The mutants of the vitamin-D-binding protein: more than 120 variants of the GC/DBP system. Vox Sang. 54: 215
    OpenUrlCrossRefPubMed
  3. ↵
    Cooke, N. E., E. V. David. 1985. Serum vitamin D-binding protein is a third member of the albumin and α fetoprotein gene family. J. Clin. Invest. 76: 2420
  4. ↵
    Yang, F., J. L. Brune, S. L. Naylor, R. L. Cupples, K. H. Naberhaus, B. H. Bowman. 1985. Human group-specific component (Gc) is a member of the albumin family. Proc. Natl. Acad. Sci. USA 82: 7994
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Haddad, J. G.. 1995. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J. Steroid Biochem. Mol. Biol. 53: 579
    OpenUrlCrossRefPubMed
  6. ↵
    Kew, R. R., R. O. Webster. 1988. Gc-globulin (vitamin D binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. J. Clin. Invest. 82: 364
  7. ↵
    Perez, H. D., E. Kelly, D. Chenoweth, F. Elfman. 1988. Identification of the C5a des Arg cochemotaxin: homology with vitamin D-binding protein (group-specific component globulin). J. Clin. Invest. 82: 360
  8. ↵
    Robbins, R. A., F. G. Hamel. 1990. Chemotactic factor inactivator interaction with Gc-globulin (vitamin D-binding protein). A mechanism of modulating the chemotactic activity of C5a. J. Immunol. 144: 2371
    OpenUrlAbstract
  9. ↵
    Petrini, M., A. Azzara, G. Carulli, F. Ambrogi, R. M. Galbraith. 1991. 1,25-dihydroxycholecalciferol inhibits the cochemotactic activity of Gc (vitamin D binding protein). J. Endocrinol. Invest. 14: 405
    OpenUrlPubMed
  10. ↵
    Metcalf, J. P., A. B. Thompson, G. L. Gossman, K. J. Nelson, S. Koyama, S. I. Rennard, R. A. Robbins. 1991. Gc-globulin functions as a cochemotaxin in the lower respiratory tract: a potential mechanism for lung neutrophil recruitment in cigarette smokers. Am. Rev. Respir. Dis. 143: 844
    OpenUrlCrossRefPubMed
  11. ↵
    Zwahlen, R. D., D. R. Roth. 1990. Chemotactic competence of neutrophils from neonatal calves: functional comparison with neutrophils from adult cattle. Inflammation 14: 109
    OpenUrlCrossRefPubMed
  12. ↵
    Piquette, C. A., R. Robinson-Hill, R. O. Webster. 1994. Human monocyte chemotaxis to complement-derived chemotaxins is enhanced by Gc-globulin. J. Leukocyte Biol. 55: 349
    OpenUrlAbstract
  13. ↵
    Senior, R. M., G. L. Griffin, H. D. Perez, R. O. Webster. 1988. Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts. J. Immunol. 141: 3570
    OpenUrlAbstract
  14. ↵
    Petrini, M., D. L. Emerson, R. M. Galbraith. 1983. Linkage between surface immunoglobulin and cytoskeleton of B lymphocytes may involve Gc protein. Nature 306: 73
    OpenUrlCrossRefPubMed
  15. ↵
    Petrini, M., R. M. Galbraith, P. A. M. Werner, D. L. Emerson, P. Arnaud. 1984. Gc (vitamin D binding protein) binds to cytoplasm of all human lymphocytes and is expressed on B-cell membranes. Clin. Immunol. Immunopathol. 31: 282
    OpenUrlCrossRefPubMed
  16. ↵
    Petrini, M., R. M. Galbraith, D. L. Emerson, A. E. Nel, P. Arnaud. 1985. Structural studies of T lymphocyte Fc receptors: association of Gc protein with IgG binding to Fcγ. J. Biol. Chem. 260: 1804
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Petrini, M., A. Allegrini, F. Ambrogi, P. Valentini, A. Sabbatini, P. Arnaud, R. M. Galbraith. 1995. Binding of Gc (VDBP) to membranes of human B lymphocytes following stripping of extant protein. J. Endocrinol. Invest. 18: 630
    OpenUrlPubMed
  18. ↵
    McLeod, J. F., M. A. Kowalski, J. G. Haddad. 1986. Characterization of a monoclonal antibody to human serum vitamin D binding protein (Gc globulin): recognition of an epitope hidden in membranes of circulating monocytes. Endocrinology 119: 77
    OpenUrlCrossRefPubMed
  19. ↵
    Kew, R. R., M. A. Sibug, J. P. Liuzzo, R. O. Webster. 1993. Localization and quantitation of the vitamin D binding protein (Gc-globulin) in human neutrophils. Blood 82: 274
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Esteban, C., M. Geuskens, J. M. Ena, Z. Mishal, A. Macho, J. M. Torres, J. Uriel. 1992. Receptor-mediated uptake and processing of vitamin D-binding protein in human B-lymphoid cells. J. Biol. Chem. 267: 10177
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Petrini, M., P. Valentini, A. Allegrini, A. Sabbatini, R. Testi, F. Ambrogi, P. Arnaud, R. M. Galbraith. 1993. Is binding of vitamin D binding protein related to cell differentiation?. Leuk. Res. 17: 561
    OpenUrlCrossRefPubMed
  22. ↵
    Gouth, M., A. Murgia, R. M. Smith, M. B. Prystowsky, N. E. Cooke, J. G. Haddad. 1990. Cell surface vitamin D-binding protein (Gc-globulin) is acquired from plasma. Endocrinology 127: 2313
    OpenUrlCrossRefPubMed
  23. ↵
    Nestler, J. E., J. F. McLeod, M. A. Kowalski, J. F. Strauss, J. G. Haddad. 1987. Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentae. Endocrinology 120: 1996
    OpenUrlCrossRefPubMed
  24. ↵
    Emerson, D. L., P. A. Werner, M. H. Cheng, R. M. Galbraith. 1985. Presence of Gc (vitamin D-binding protein) and interactions with actin in human placental tissue. Am. J. Reprod. Immunol. 7: 15
  25. ↵
    Wooten, M. W., A. E. Nel, P. J. Goldschmidt-Clermont, R. M. Galbraith, R. W. Wrenn. 1985. Identification of a major endogenous substrate for phospholipid/Ca2 ± dependent kinase in pancreatic acini as Gc (vitamin D-binding protein). FEBS Lett. 191: 97
    OpenUrlCrossRefPubMed
  26. ↵
    Keenan, M. J., R. P. Holmes. 1991. The uptake and metabolism of 25-hydroxyvitamin D3 and vitamin D binding protein by cultured porcine kidney cells (LLC-PK1). Int. J. Biochem. 23: 1225
    OpenUrlCrossRefPubMed
  27. ↵
    Yu, H. M., X. J. Li, A. L. Kadam, C. Y. Cheng, S. S. Koide. 1994. Human testis vitamin D binding protein involved in infertility. Arch. Androl. 33: 119
    OpenUrlCrossRefPubMed
  28. ↵
    Kew, R. R., K. W. Mollison, R. O. Webster. 1995. Binding of Gc globulin (vitamin D binding protein) to C5a or C5a des Arg is not necessary for co-chemotactic activity. J. Leukocyte Biol. 58: 55
    OpenUrlAbstract
  29. ↵
    Kew, R. R., J. A. Fisher, R. O. Webster. 1995. Co-chemotactic effect of Gc-globulin (vitamin D binding protein) for C5a: transient conversion into an active co-chemotaxin by neutrophils. J. Immunol. 155: 5369
    OpenUrlAbstract
  30. ↵
    Borregaard, N., J. M. Heiple, E. R. Simons, R. A. Clark. 1983. Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation. J. Cell Biol. 97: 53
    OpenUrl
  31. ↵
    Kjeldsen, L., H. Sengelov, K. Lollike, M. H. Nielsen, N. Borregaard. 1994. Isolation and characterization of gelatinase granules from human neutrophils. Blood 83: 1640
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Laemmli, U. K.. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680
    OpenUrlCrossRefPubMed
  33. ↵
    Helenius, A., K. Simons. 1975. Solubilization of membranes by detergents. Biochim. Biophys. Acta 415: 29
    OpenUrlPubMed
  34. ↵
    Ji, T. H., C. R. Middaugh. 1980. Does random collisional cross–linking occurr?. Biochim. Biophys. Acta 603: 371
    OpenUrlPubMed
  35. ↵
    Jesaitis, A. J., K. N. Klotz. 1993. Cytoskeletal regulation of chemotactic receptors: molecular complexation of N–formyl peptide receptors with G proteins and actin. Eur. J. Haematol. 51: 288
    OpenUrlPubMed
  36. ↵
    Sheterline, P., C. R. Hopkins. 1981. Transmembrane linkage between surface glycoproteins and components of the cytoplasm in neutrophil leukocytes. J. Cell Biol. 90: 743
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Davies, A. A., N. M. Wigglesworth, D. Allan, R. J. Owens, M. J. Crumpton. 1984. Nonidet P-40 extraction of lymphocyte plasma membrane. Biochem. J. 219: 301
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Luna, E. J., A. L. Hitt. 1992. Cytoskeleton-plasma membrane interactions. Science 258: 955
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Yan, S. R., L. Fumagalli, S. Dusi, G. Berton. 1995. Tumor necrosis factor triggers redidtribution to a Triton X–100–insoluble, cytoskeletal fraction of β2 integrins, NADPH oxidase components, tyrosine phosphorylated proteins, and the protein tyrosine kinase p58fgr in human neutrophils adherent to fibrinogen. J. Leukocyte Biol. 58: 595
    OpenUrlAbstract
  40. ↵
    Bertagnolli, M. E., M. C. Berkerle. 1993. Evidence for the selective assocaition of a subpopulation of GPIIb–IIIa with the actin cytoskeletons of thrombin-activated platelets. J. Cell Biol. 121: 1329
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Perschl, A., J. Lesley, N. English, R. Hyman, I. S. Trowbridge. 1995. Transmembrane domain of CD44 is required for its detergent insolubility in fibroblasts. J. Cell Sci. 108: 1033
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Brown, D. A., J. K. Rose. 1992. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 68: 533
    OpenUrlCrossRefPubMed
  43. ↵
    Brown, D. A., E. London. 1998. Functions of lipid rafts in biological membranes. Annu. Rev. Cell. Dev. Biol. 14: 111
    OpenUrlCrossRefPubMed
  44. ↵
    Woods, A., J. R. Couchman, M. Hook. 1985. Heparan sulfate proteoglycans of rat embryo fibroblasts. J. Biol. Chem. 260: 10872
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Rapraeger, A., M. Jalkanen, M. Bernfield. 1986. Cell surface proteoglycan assocaites with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells. J. Cell Biol. 103: 2683
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Carey, D. J., M. S. Todd. 1986. A cytoskeleton-associated plasma membrane heparan sulfate proteoglycan in schwann cells. J. Biol. Chem. 261: 7518
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Carey, D. J., C. M. Rafferty, M. M. Schramm. 1987. Assocaition of heparan sulfate proteoglycan and laminin with the cytoskeleton in rat liver. J. Biol. Chem. 262: 3376
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Miettinen, H. M., M. Jalkanen. 1994. The cytoplasmic domain of syndecan–1 is not required for association with Triton X-100-insoluble material. J. Cell Sci. 107: 1571
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Fransson, L.. 1981. Self-association of bovine lung heparan sulfates: identification and characterization of contact zones. Eur. J. Biochem. 120: 251
    OpenUrlPubMed
  50. ↵
    Fransson, L., B. Havsmark. 1982. Structural requirements for heparan sulfate self-association. Carbohydr. Res. 110: 135
    OpenUrlCrossRefPubMed
  51. ↵
    Kapoor, R., C. F. Phelps, T. N. Wight. 1986. Physical properties of chondroitin sulfate/dermatan sulfate proteoglycans from bovine aorta. Biochem. J. 240: 575
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Elenius, K., M. Jalkanen. 1994. Function of the syndecans: a family of cell surface proteoglycans. J. Cell Sci. 107: 2975
    OpenUrlFREE Full Text
  53. ↵
    Carey, D. J.. 1997. Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327: 1
  54. ↵
    Petersen, F., L. Bock, H. D. Flad, E. Brandt. 1998. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J. Immunol. 161: 4347
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

In this issue

The Journal of Immunology: 163 (4)
The Journal of Immunology
Vol. 163, Issue 4
15 Aug 1999
Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section